Related by context. All words. (Click for frequent words.) 83 phase IIa 81 Phase Ib 81 phase IIa clinical 80 Phase IIb trial 79 Phase IIb 79 phase IIb clinical 79 Phase 2b clinical 79 Phase Ib clinical 79 Phase III clinical 78 Phase IIb clinical 78 Phase 2b study 77 Phase IIIb clinical 77 phase IIb trial 77 Phase III 77 Phase 2a clinical 77 Phase IIa clinical 77 Phase Ib study 77 phase Ib 77 Phase 1b clinical 77 Phase 2a trial 76 Phase Ib II 76 Phase IIa 76 Phase 2a 76 phase 2a 76 pivotal Phase III 76 Phase 1b trial 76 Phase IIa trial 76 Phase 1b 76 multicenter Phase 75 Phase 2b trial 75 elotuzumab 75 Phase 2b 75 Phase IIB 75 Phase IIb trials 75 placebo controlled Phase 75 Phase 1a 75 dose escalation Phase 74 Phase #b/#a 74 multicenter Phase II 74 Phase 1a clinical 74 Phase #/#a 74 Phase 2b clinical trials 73 Phase III trials 73 Phase IIIb 73 Phase IIa trials 73 BRIM3 73 phase Ib clinical 73 phase IIb study 73 randomized Phase IIb 73 Phase IIb clinical trials 73 confirmatory Phase III 73 Phase Ia 72 Phase II 72 APEX PD 72 Phase III clinical trials 72 alvespimycin 72 oral ridaforolimus 72 JAK inhibitor 71 clinical trial 71 Phase III pivotal 71 HuMax EGFr 71 randomized Phase III 71 randomized Phase 71 BRIM2 71 ocrelizumab 71 dose escalation trial 71 viral kinetic 71 randomized controlled Phase 71 Bicifadine 71 fostamatinib 71 registrational 70 bicifadine 70 placebo controlled Phase III 70 RSD# oral 70 initiate Phase IIb 70 confirmatory Phase 3 70 phase IIb III 70 placebo controlled clinical 70 SUCCEED trial 70 teriflunomide 70 blinded randomized placebo controlled 70 midstage trials 70 phase IIIb 70 LUX Lung 70 pivotal bioequivalence 70 multicenter phase 70 multicenter randomized placebo controlled 70 Phase Ib clinical trials 70 GALNS 70 TASKi2 70 Initiate Phase 70 double blinded placebo 70 randomized Phase 2b 70 ongoing Phase 1b 69 registrational trial 69 dose escalation clinical 69 confirmatory clinical 69 Phase III randomized controlled 69 FOLOTYN ® 69 NO# [002] 69 double blinded randomized 69 PRT# 69 midstage clinical 69 pivotal Phase 69 BCX# 69 Dacogen injection 69 ADVANCE PD 69 Quinamed 69 TBC# 69 HGS# 69 ganetespib 69 INCB# [001] 69 dirucotide 69 multicenter Phase III 69 SAR# [004] 69 cannabinor 69 Corlux 69 ENDEAVOR IV 69 randomized multicenter 69 pharmacokinetic PK 69 axitinib 69 multicentre randomized 69 selective androgen receptor modulator 69 PROSTVAC TM 69 Plicera 68 Phase IIb III 68 lintuzumab 68 ANCHOR trial 68 dose cohort 68 PDE4 inhibitor 68 MERLIN TIMI 68 bardoxolone 68 vicriviroc 68 sunitinib malate 68 CHAMPION PCI 68 pharmacokinetic PK study 68 HCV SPRINT 68 pertuzumab 68 Randomized Phase 68 IIa clinical 68 Allovectin 7 68 Asentar 68 docetaxel Taxotere R 68 tanespimycin 68 L BLP# 68 Mipomersen 68 IIa trial 68 NVA# 68 huC# DM4 68 ProSavin 68 Amrubicin 68 Phase Ib IIa 68 Pivotal Phase III 68 neratinib 68 PSN# [002] 68 NP2 Enkephalin 68 Phase #b/#a clinical 68 PANVAC VF 68 OncoVEX GM CSF 68 AEGR 68 ASA# 68 mipomersen 68 Pivotal Phase 68 Phase 2a clinical trials 68 clinical pharmacology studies 68 MEND CABG 68 TMC# C# 68 ORAL Sync 68 aclidinium bromide 67 Phase III placebo controlled 67 daclizumab 67 Phase IIa clinical trials 67 trastuzumab DM1 T DM1 67 brivaracetam 67 Archexin 67 Zenvia Phase III 67 OvaRex ® MAb 67 Phenoptin 67 Safinamide 67 HuMax CD4 67 obatoclax 67 velafermin 67 lomitapide 67 multicenter clinical 67 Zerenex 67 fidaxomicin Phase 3 67 Phase 67 Cloretazine ® 67 rALLy clinical trial 67 Phase III confirmatory 67 clinical trials 67 CRLX# 67 Oglemilast 67 diabetic neuropathic pain 67 R#/MEM # 67 Initiated Phase 67 dose escalation 67 Pivotal Trial 67 budesonide foam 67 PRE SURGE 67 oral prodrug 67 PEG SN# 67 forodesine 67 ularitide 67 GetGoal Phase III 67 multicenter randomized Phase 67 Phase IIb Trial 67 HuMax CD# 67 TELCYTA 67 Laquinimod 67 custirsen 67 CR# vcMMAE 67 GLP toxicology studies 67 Annamycin 67 glufosfamide 66 IMA# 66 Desmoteplase 66 Sym# 66 teduglutide 66 virus HCV protease inhibitor 66 BAY #-# 66 PREOS R 66 placebo controlled randomized 66 AEG# 66 mertansine 66 Phase III Clinical Trials 66 Urocidin 66 PREOS 66 initiate Phase 2b 66 CoFactor 66 Lu AA# 66 torezolid phosphate 66 LCP AtorFen 66 Aurexis 66 riociguat 66 TACI Ig 66 Phase III Clinical Trial 66 KRN# 66 Phase 1b clinical trials 66 IND submission 66 IMC A# 66 relapsed refractory multiple myeloma 66 MAGE A3 ASCI 66 reslizumab 66 HGS ETR1 66 prospective multicenter 66 TMC# [002] 66 methylnaltrexone 66 Phase 2b kidney transplant 66 Phase III Pivotal 66 EndoTAG TM -1 66 GAMMAGARD 66 ENDEAVOR III 66 multiple ascending dose 66 APTIVUS 66 ToGA 66 Phase #b/#a trial 66 PFO migraine 66 antibody MAb 66 valopicitabine 66 masked placebo controlled 66 deforolimus 66 placebo controlled 66 enzastaurin 66 dose escalation study 66 Nuvion 66 TOCOSOL Paclitaxel 66 trastuzumab emtansine T DM1 66 tesmilifene 66 Tarceva TM 66 BLA filing 66 oral deforolimus 66 MAA submission 66 AeroLEF TM 66 Vitaxin 66 tremelimumab 66 aclidinium 66 Phase 2b monotherapy 66 evaluating tivozanib 66 leading oral taxane 66 safinamide 66 LAF# 66 Relovair 66 PEG Interferon lambda 66 elacytarabine 66 Ostarine 66 randomized controlled multicenter 66 multicenter randomized double 66 vidofludimus 66 ACTEMRA TM 66 AZILECT R 65 IL# PE#QQR 65 pharmacokinetics PK 65 prospective randomized placebo 65 multicenter randomized controlled 65 YONDELIS 65 APPRAISE 65 trastuzumab DM1 65 Fx #A 65 Androxal TM 65 dose cohorts 65 RGB # 65 INCB# [002] 65 Fodosine 65 PSMA ADC 65 metastatic hormone refractory 65 ABSORB trial 65 multicenter placebo controlled 65 Daclizumab 65 blind randomized placebo 65 RE LY ® 65 rindopepimut 65 randomized multicenter trial 65 PXD# 65 Phase III randomized 65 baminercept 65 CEQ# 65 receptor tyrosine kinase inhibitor 65 Traficet EN 65 cetuximab Erbitux 65 Viramidine 65 LibiGel Phase III 65 randomized blinded 65 randomized multicenter Phase III 65 relapsed multiple myeloma 65 TLK# 65 assessing T DM1 65 dosing cohorts 65 APEX AMI trial 65 pradefovir 65 Pimavanserin 65 ELACYT 65 RE LY 65 Phase III psoriasis 65 ISIS # 65 opioid induced bowel dysfunction 65 liposomal formulation 65 RE SURGE 65 nalbuphine ER 65 VEGF Trap 65 JZP 65 GOUT 65 AVERROES 65 GSK# [002] 65 IMC #B 65 CDP# 65 rALLy trial 65 AVADO 65 TG MV 65 IMGN# 65 AQ4N 65 placebo controlled clinical trials 65 active comparator 65 entinostat 65 celgosivir 65 ONCONASE R 65 subanalysis 65 ATL# [001] 65 Phase IIIb study 65 eniluracil 65 Sulonex 65 randomized controlled clinical 65 Aflibercept 65 BCIRG 65 tolevamer 65 Phase III TRIST 65 LUMINATE 65 HCV RESPOND 2 65 EDEMA3 65 randomized clinical 65 Phase III Trial 65 TASKi3 65 AP# [003] 65 QNEXA 65 nab paclitaxel 65 IIb clinical trial 65 Alzhemed TM 65 dyskinesia PD LID 65 DU #b 65 ZACTIMA 65 MEND CABG II 65 PRIMO CABG 65 almorexant 65 including eniluracil ADH 65 XL# SAR# 65 IDX# 65 elagolix 65 cangrelor 65 PRX # 65 ruxolitinib 65 Prostate AdenoCarcinoma Treatment 65 COMFORT II 65 Phase 1b dose escalation 64 Nasulin 64 CBLC# 64 dacetuzumab 64 ZYBRESTAT 64 romidepsin 64 omacetaxine mepesuccinate 64 AZILECT ® 64 European Sepsis Trial 64 ELND# 64 initiate Phase Ib 64 Multiple Ascending Dose 64 ILLUMINATE 64 IND enabling 64 BRAF inhibitor 64 MYDICAR 64 Clonicel 64 Canvaxin 64 laquinimod 64 Zenvia ™ 64 midstage studies 64 dexanabinol 64 severe hypercholesterolemia 64 cathepsin K inhibitor 64 alemtuzumab Campath 64 ospemifene 64 EOquin TM 64 MAP# 64 prospective randomized multicenter 64 Phase III HEAT 64 Aplidin 64 RSD# 64 Civacir 64 visilizumab 64 initiate Phase 1b 64 Xanafide 64 ozarelix 64 Tesetaxel 64 ofatumumab HuMax CD# 64 ROCKET AF 64 DermaVir Patch 64 dose dose escalation 64 satraplatin Phase 64 single ascending dose 64 ALN VSP Phase 64 interferon gamma 1b 64 iniparib 64 TroVax 64 BOLDER II 64 thorough QT 64 Gattex 64 Nexavar sorafenib 64 Board DSMB 64 generation purine nucleoside 64 betrixaban 64 candidate CRLX# 64 atacicept 64 efficacy endpoint 64 investigational pan BCR 64 Synavive 64 NOX E# 64 NGX# 64 GLPG# 64 Serada 64 eprotirome 64 Ixempra 64 edoxaban 64 phase III ACCLAIM 64 RELOVAIR ™ 64 zanolimumab 64 pharmacokinetic studies 64 Proxinium TM 64 sapacitabine 64 Phase III VISTA 64 isavuconazole 64 HCD# [002] 64 dexpramipexole 64 ulimorelin 64 TEMSO 64 nonclinical studies 64 SPIRIT FIRST 64 clazosentan 64 Naproxcinod 64 ponatinib 64 Zybrestat 64 Phase lll 64 EMPHASIS HF trial 64 initiated Phase Ib 64 Urocortin 2 64 TRO# 64 photoprotective drug 64 multicenter prospective 64 DEB# 64 aflibercept 64 trial evaluating PRX# 64 PEG PAL 64 investigational compound 64 PHX# 64 ExTRACT TIMI 64 mGluR5 NAM 64 CLARITY study 64 Ophena TM 64 preclinical efficacy 64 prospective randomized controlled 64 subcutaneously administered 64 placebo controlled studies 64 evaluating Actimmune 64 II Clinical Trial 64 afatinib 64 Apixaban 64 Tanespimycin 64 MAXY alpha 64 lorvotuzumab mertansine 64 Elagolix 64 RhuDex ® 64 dimebon 64 HQK 64 tramiprosate Alzhemed TM 64 denufosol 64 ILUVIEN ® 64 investigational protease inhibitor 64 KNS # 64 belinostat 64 maximally tolerated dose 64 Cinquil 64 Cloretazine R VNP#M 64 PRECiSE 64 Proellex TM 64 subcutaneous formulation 64 Intervention Effectiveness 64 QVA# 64 eltrombopag 64 GV# [001] 64 Ambrisentan 64 albinterferon alfa 2b 64 oral rivaroxaban 64 Randomized Phase II 64 MIST II 64 farletuzumab 64 multicenter randomized 64 afamelanotide 64 QLT# 64 STRIDE PD 64 IMPACT IMmunotherapy 64 AVE# 64 BLOOM DM 64 Alocrest 63 compound INCB# 63 metaglidasen 63 unblind 63 carfilzomib 63 Exherin TM 63 rNAPc2 63 tezampanel NGX# 63 Azedra 63 metastatic castration resistant 63 BR.# 63 Phase 2b randomized 63 cediranib 63 budesonide MMX 63 vascular disrupting agent 63 prospective multicenter randomized 63 Acapodene 63 ADAGIO study 63 AIM HIGH 63 CUSTOM III 63 randomized placebo controlled 63 Locteron ® 63 oral methylnaltrexone 63 blinded randomized 63 Amigal 63 sorafenib Nexavar 63 LymphoStat B TM 63 SYMMETRY trial 63 Onrigin 63 Ozarelix 63 LibiGel ® 63 Panzem R NCD 63 seliciclib CYC# 63 alvimopan 63 R#/MEM 63 Ketotransdel 63 peginesatide 63 Denufosol 63 EURIDIS 63 DAPT 63 canakinumab 63 unblinding 63 ONTARGET 63 Spiegelmer ® 63 non nucleoside HCV 63 Phase IIa proof 63 docetaxel chemotherapy 63 fosbretabulin 63 velafermin belinostat 63 refractory CLL 63 darapladib 63 GW# [003] 63 refractory metastatic colorectal cancer 63 treatment naive genotype 63 HGS ETR2 63 refractory gout 63 thymalfasin 63 SAR# [002] 63 VNP#M 63 incyclinide 63 Azedra TM 63 arzoxifene 63 Dose escalation 63 mapatumumab 63 CCR5 antagonist 63 CCX# B 63 octreotide implant 63 Aryplase 63 cilengitide 63 mGluR5 negative 63 TASQ 63 ORACLE MS 63 EGS# 63 SinuNase 63 SNT MC# 63 ACAPODENE 63 investigational humanized monoclonal antibody 63 Omnitarg 63 Triolex 63 randomized multicentre 63 PRECISE trial 63 ascending dose 63 bosutinib 63 PF # [002] 63 ancrod 63 VITAL Trial 63 CB2 selective receptor agonist 63 Locteron 63 Diamyd ® 63 adecatumumab 63 CIMZIA TM 63 Darusentan 63 vosaroxin 63 unblinded 63 DSMB 63 RRMS patients 63 Cetrorelix 63 CRx 63 PA# [002] 63 IIa clinical trial 63 apremilast 63 Ocrelizumab 63 bortezomib Velcade 63 phase III isavuconazole 63 Romidepsin 63 T DM1 63 pegloticase 63 DDP# 63 Fibrin Pad 63 Menerba 63 Sigma Tau SpA 63 eosinophilic asthma 63 CRMD# 63 metastatic HRPC 63 MBP# [001] 63 RG# [001] 63 MOZOBIL 63 HuLuc# 63 BrachySil 63 UPLYSO 63 ALN TTR# 63 Serdaxin ® 63 Dapagliflozin 63 Tezampanel 63 Actilon 63 ixabepilone 63 preclinical 63 atrasentan 63 Luveniq 63 controlled multicenter 63 ketolide antibiotic 63 galiximab 63 zalutumumab 63 ITAX 63 IIa trials 63 Alfimeprase 63 muraglitazar 63 Phase III multicenter 63 Phase 2b Clinical Trial 63 desvenlafaxine succinate 63 Phase III metastatic melanoma 63 Ophena 63 Cloretazine 63 Glufosfamide 63 OncoVEX 63 regorafenib 63 EOquin 63 GLYX 63 randomized discontinuation trial 63 Tyrima 63 label dose escalation 63 Troxatyl 63 RhuDex 63 generation PNP inhibitor 63 lixisenatide 63 PRTX 63 ACCLAIM II 63 pomalidomide 63 OHR/AVR# 63 label multicenter 63 ASONEP 63 Capesaris 63 tecarfarin 63 LAS# [002] 63 acyclovir Lauriad R 63 Omacetaxine 63 vemurafenib 63 lumiliximab 63 fidaxomicin Phase 63 sodium thiosulfate STS 63 Degarelix 63 Factor VIIa 63 investigational monoclonal antibody 63 Allovectin 7 ® 63 Phase 2a Clinical Trial 63 ECASS 63 palifosfamide 63 EVIZON 63 midstage clinical trials 63 aleglitazar 63 NABTT 63 ThGRF 63 bazedoxifene 63 PEG IFN 63 Vicriviroc 63 CCX# 63 volociximab 63 miconazole Lauriad ® 63 Saxagliptin 63 CA4P 63 oxypurinol 63 ZYBRESTAT fosbretabulin 63 anticancer compound 63 dosing cohort 63 tolerated dose MTD 63 PDX pralatrexate 63 tiapamil 63 Anturol TM 63 DR Cysteamine 63 GSK# [001] 63 orBec 63 EVEREST II 62 double blind placebo 62 GRN# 62 oxymorphone ER 62 label multicenter Phase 62 talactoferrin 62 otelixizumab 62 adecatumumab MT# 62 TOLAMBA 62 OncoGel 62 lapatinib Tykerb 62 FTY# fingolimod 62 TELINTRA 62 crizotinib PF # 62 CLORETAZINE TM VNP#M 62 Dextofisopam 62 Aurora kinase inhibitor 62 Aptivus ® 62 SPIRIT IV 62 Pazopanib 62 Lupuzor 62 Orazol 62 candidates Dyloject TM 62 posaconazole 62 Reverset 62 TKM ApoB 62 investigational antiplatelet agent 62 inhibitor RG# 62 Matrix Phase 2b 62 ATTRACT 62 Pegasys plus Copegus 62 Afatinib 62 glucokinase activator 62 multicenter 62 evaluating satraplatin 62 lorcaserin Phase 62 cetrorelix 62 TRANSFORMS 62 Carfilzomib 62 Lodotra TM 62 Zemplar Capsules 62 Nasdaq ACHN 62 sunitinib 62 aflibercept VEGF Trap 62 cariprazine 62 motesanib 62 PD LID 62 NSABP B 62 Fibrillex TM 62 LCP Tacro 62 Phase III ALLEGRO 62 Torisel 62 randomized controlled 62 CALGB 62 prucalopride 62 trodusquemine 62 Rebif ® 62 lintuzumab SGN 62 XL# XL# XL# 62 TKB# 62 trabedersen 62 vandetanib 62 confirmatory Phase 62 TPI ASM8 62 Medidur TM FA 62 Betaferon ® 62 PROMACTA 62 DXL# 62 Phase IIb Clinical Trial 62 ABSORB clinical 62 blinatumomab 62 HCV protease inhibitor 62 ThermoDox R 62 Kynapid 62 Dalbavancin 62 controlled multicenter Phase 62 XmAb# 62 rilonacept 62 metastatic castrate resistant 62 MLN# 62 NV1FGF 62 ritonavir boosted danoprevir 62 ACTIVE W 62 Pirfenidone 62 GVAX 62 Xelox 62 EXPLORE Xa 62 OPT CHF 62 integrase inhibitor 62 apricitabine 62 OncoVex 62 bendamustine 62 bevacizumab Avastin 62 darusentan 62 Sular formulation 62 SinuNase TM 62 Inhalation Solution 62 multicentre randomized double 62 DB# [003] 62 cetuximab Erbitux R 62 Dual Opioid 62 dose escalation phase 62 ORENCIA ® 62 Blinatumomab 62 AERAS-#/Crucell Ad# 62 initiate Phase IIa 62 ruboxistaurin 62 Targretin 62 Vernakalant 62 postoperative ileus POI 62 Exherin 62 CLL8 62 PF # [001] 62 ritonavir boosted 62 PS# DARA 62 hypoxia activated prodrug 62 Phase IIA 62 metastatic sarcomas 62 Ereska 62 multicenter multinational 62 perifosine 62 Clolar ® 62 Bezielle 62 Hyphanox 62 Ceflatonin 62 PEARL SC 62 prospective observational 62 Deforolimus 62 Vilazodone 62 telaprevir VX 62 Stedivaze 62 adipiplon 62 Phase III ThermoDox 62 senicapoc 62 BLA submission 62 Clinical Antipsychotic Trials 62 placebo controlled trials 62 Pafuramidine 62 Rezular 62 Phase #/#a trial 62 Augment Injectable 62 EchoCRT 62 Enzastaurin 62 evaluating mipomersen 62 Initiates Phase II 62 temsirolimus 62 OvaRex 62 tezampanel 62 Taxotere ® 62 DASISION 62 ofatumumab 62 dextromethorphan quinidine 62 interferon beta 1b 62 MKC# MT 62 resminostat 62 NATRECOR R 62 SCH # 62 pafuramidine 62 sNDA submission 62 Panitumumab 62 AIR CF2 62 Virulizin ® 62 relapsing remitting multiple sclerosis 62 AIR CF1 62 oral taxane 62 OvaRex R 62 figitumumab 62 Nexavar ® 62 oral treprostinil 62 Allovectin 7 R 62 preclinical pharmacokinetic 62 REOLYSIN ® 62 MADIT II 62 Altastaph 62 Trandolapril 62 evaluating REVLIMID 62 MEK inhibitor RDEA# 62 Neupro R 62 NASDAQ CXSP announced 62 LBH# 62 Oral NKTR 62 ridaforolimus 62 PEP# [003] 62 balsalazide tablet 62 LEVADEX ™ 62 PHASE III 62 corticosteroid dexamethasone 62 IMPACT DCM 62 MIRCERA 62 albiglutide 61 EDEMA4 61 docetaxel Taxotere ® 61 BiTE R 61 Phase #/#a clinical 61 CYT# QbG# 61 TAXUS ATLAS 61 prospective randomized 61 Omigard 61 AVOREN 61 indibulin 61 REVIVE Diabetes 61 Cimzia TM 61 MYDICAR ® 61 Phase 2b Trial 61 pharmacokinetic pharmacodynamic 61 viral kinetics 61 Prosaptide 61 ACTEMRA 61 diarrhea predominant irritable 61 ataluren 61 desvenlafaxine 61 CRD5 61 DSMB recommended 61 prodrug stimulant 61 Serdaxin 61 novel VDA molecule 61 initiate Phase 61 investigational hepatitis C 61 multicentre 61 secondary efficacy endpoints 61 Gabapentin GR 61 Iloperidone 61 Vectibix panitumumab 61 CTAP# Capsules 61 CYT# 61 tasimelteon 61 Study Evaluating 61 ENDEAVOR II 61 relapsed MM 61 Golimumab 61 SILENOR 61 vernakalant oral 61 preclinical toxicology 61 PROSTVAC ® 61 Zoraxel 61 radiation sensitizer 61 VELCADE melphalan 61 urocortin 2 61 EndoTAG 61 initiate Phase 2a 61 PLK1 SNALP 61 olaparib 61 Tarvacin TM 61 BENLYSTA ® 61 relapsing multiple sclerosis 61 LymphoStat B 61 ARDIS 61 registrational Phase 61 Tocosol Paclitaxel 61 treatment naïve genotype 61 Myocet 61 Phase 2a Study 61 SUTENT ® 61 Cangrelor 61 varespladib 61 rEV# 61 glatiramer acetate 61 Testosterone MDTS ® 61 MIVI III 61 Ziopharm